Author

J. E. Ledgerwood

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Approach:statistical model· 1

Frequent Co-Authors

B. S. Graham· 4 shared J. R. Mascola· 3 shared A. McDermott· 2 shared A. Pegu· 2 shared A. T. Widge· 2 shared C. A. Talana· 2 shared D. C. Douek· 2 shared D. R. Martinez· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

B. S. Graham

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings

K. L. Boswell, T. Watkins, E. M. Cale, J. Samsel, S. F. Andrews, D. R. Ambrozak, J. I. Driscoll, M. A. Messina, S. Narpala, C. S. Hopp, A. Cagigi, J. P. Casazza, T. Yamamoto, T. Zhou, W. R. Schief, , R. A. Koup

This study applies Bcl-6/Bcl-xL retroviral transduction to isolate antibodies and generate B cell clones from various B cell populations in healthy and infected individuals.

bioRxiv · Mar 29, 2022Immunology

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

A. Pegu, S. E. O'Connell, S. D. Schmidt, S. O'Dell, C. A. Talana, L. Lai, J. Albert, E. Anderson, H. Bennett, K. Corbett, B. Flach, L. Jackson, B. Leav, J. E. Ledgerwood, C. J. Luke, , N. A. Doria-Rose

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

bioRxiv · May 13, 2021 · PreprintImmunology

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

L. Wang, T. Zhou, Y. Zhang, E. S. Yang, C. A. Schramm, W. Shi, A. Pegu, O. K. Oloninyi, A. Ransier, S. Darko, S. R. Narpala, C. Hatcher, D. R. Martinez, Y. Tsybovsky, E. Phung, , Mascol

The paper identifies ultrapotent antibodies from convalescent donors that neutralize SARS-CoV-2 variants and reduce escape mutant generation.

bioRxiv · Feb 25, 2021Immunology

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

M. Gutierrez-Gonzalez, A. S. Fahad, M. Ardito, P. Nanaware, L. Lu, E. Normandin, B. Madan, J. Tivin, E. Coates, A. R. Henry, F. Laboune, B. S. Graham, D. C. Douek, J. E. Ledgerwood, J. R. Mascola, , B. J. DeKosky

The paper shows that MHC-II epitope removal from BCRs correlates with antibody development, T cell help, and long-term serum antibody secretion.

bioRxiv · Jan 15, 2021 · PreprintImmunology

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

A. R. Shiakolas, K. J. Kramer, D. Wrapp, S. I. Richardson, A. Schäfer, S. Wall, N. Wang, K. Janowska, K. A. Pilewski, R. Venkat, R. Parks, N. P. Manamela, N. Raju, E. Friedman Fechter, C. M. Holt, , I. S. Georgiev

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

bioRxiv · Dec 20, 2020 · PreprintImmunology